相关实验视频

Updated: May 5, 2026

Oral Biofilm Formation on Different Materials for Dental Implants

Oral Biofilm Formation on Different Materials for Dental Implants

Published on: June 24, 2018

和甲联合功能化的聚乙:一种针对老年人的新型牙植入物材料

Zhengwei Liu¹, Enze Zhao², Yansong Wang³

¹Department of Orthopedics, Northern Jiangsu People's Hospital, Clinical Teaching Hospital of Medical School, Nanjing University, Yangzhou, Jiangsu, PR China.

Journal of advanced research

|August 29, 2025

概括

这项研究开发了ZnMet@PEEK,一种新的牙科植入物材料,通过减少炎症和细胞衰老来增强老年患者的骨质整合. 对于与年龄相关的骨再生问题,ZnMet@PEEK提供了一个有前途的解决方案.

科学领域:

生物材料科学
复原医学
老年牙科

背景情况:

老年人牙科植入物患者因与年龄相关的骨再生衰退,包括Wnt/β-catenin信号减少,细胞衰老和炎症而面临挑战.
在老年人中,衰老骨质细胞通过骨质发生障碍,慢性炎症和免疫骨脱导致骨髓损失.
聚乙基 (PEEK) 是一种潜在的牙科植入物材料,因为它具有类似骨的弹性模块,但其生物惰性阻碍了骨质整合.

研究的目的:

通过结合 (Zn) 和甲 (Met) 来开发一个功能化的PEEK衍生品,ZnMet@PEEK.
在老年患者中增强牙植入物与气泡骨的骨质融合.
解决与年龄相关的骨质再生障碍,提高老年人群的植入成功率.

主要方法:

通过使用多巴胺辅助的物理粘附来合成ZnMet@PEEK,将Zn的抗炎/骨质生成特性与Met的抗衰老作用相结合.
使用CCK8,活体/死体染色,RT- qPCR,免疫光和ELISA进行了体外生物相容性和骨质细胞分化评估.
在老老老鼠身上使用微型CT和组织学分析评估骨质整合.

主要成果:

材料表征证实成功地将ZnMet纳入PEEK表面.
在试验室中,ZnMet@PEEK显示出优异的生物相容性,显著降低了炎症,并促进了骨质分化.
在老老鼠体内研究表明,ZnMet@PEEK通过抑制细胞衰老和促进骨形成来增强骨质整合.

结论:

一种新的功能化PEEK衍生品ZnMet@PEEK已成功开发出来,具有抗炎症,骨质生成和抗衰老的特性.
ZnMet@PEEK为老年人的牙科植入物提供了定制的解决方案,解决了骨质整合方面的挑战.
这种材料为改善老年患者的牙科植入物结果提供了有前途的进展.

关键词:

牙植入物骨质整合骨质细胞衰老聚乙基表面的修改

更多相关视频

Direct and Indirect Culture Methods for Studying Biodegradable Implant Materials In Vitro

Direct and Indirect Culture Methods for Studying Biodegradable Implant Materials In Vitro

Published on: April 15, 2022

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Surgical Bone Implantation Technique for Rat Tibia Models of Diabetes and Osteoporosis

Published on: July 5, 2024

相关概念视频

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...